Editor's Note: Patient Worthy is honored to share this article from Rareatives, originally written by our friend Jessica Lynn. To see the article in its original format, please click here.…
Editor's Note: Patient Worthy is honored to share this story from our friends at Elephants & Tea, originally written by Bill Phillips, a colorectal cancer survivor. To see the article…
A single genetic change can have dramatically different effects from one person to the next. That is the reality for people living with PTEN hamartoma tumour syndrome (PHTS), a rare…
As reported on QZ, the U.S. Food and Drug Administration has approved a new indication for Eli Lilly’s tirzepatide (Mounjaro), allowing the therapy to be used to reduce the risk…
As reported on MedCity News, the U.S. Food and Drug Administration has approved Takeda Pharmaceutical’s Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare…
As reported on Drugs, BioNTech has decided to halt development of its Phase 2 BNT122-01 study investigating autogene cevumeran (BNT122/RO7198457) in patients with resected colorectal cancer who remained ctDNA-positive after…
As reported on PharmaBiz, BeOne Medicines has reported positive results from the second interim analysis of the phase 3 HERIZON-GEA-01 trial, further supporting the use of zanidatamab (Ziihera)-containing regimens as…
At 22, a young person's world should be filled with possibilities—a career to build, places to travel, friendships to make, and a future to imagine. Instead, this young man, David,…
As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has granted approval to PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythaemia (ET), providing…
In a recent press release, Novartis has reported positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials, showing that the investigational oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib…
As reported on Business Wire, the European Commission has approved trastuzumab deruxtecan (Enhertu) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.…
As reported in the European Medical Journal, Novartis has paused eight clinical studies evaluating its experimental CAR-T cell therapy, known as rap-cell, after three trial participants died following severe immune-related…
As reported in the European Medical Journal, new research suggests that cherry angiomas occur more frequently and at an earlier age in people with neurofibromatosis type 1 (NF1), raising the…
In a recent press release, BioCryst Pharmaceuticals has shared that it received approval from Japan’s Ministry of Health, Labour and Welfare for the use of ORLADEYO® (berotralstat) as a preventive…
As reported on Inside Precision Medicine, a new, non-invasive test may help doctors detect oral cancer quickly and reduce the need for painful scalpel biopsies. In a large study involving…
Have you ever looked in the mirror and wondered, “Who am I now? Why did this diagnosis happen to me? When will this be over? Who will ever love me…
As reported on Pharma Phorum, Roivant Sciences and its subsidiary Priovant Therapeutics have received U.S. Food and Drug Administration (FDA) approval for Lisraya (brepocitinib), marking the first targeted treatment specifically…
As reported on Business Wire, AstraZeneca has finalized its previously announced licensing agreement with Dizal Pharmaceutical, gaining exclusive worldwide rights to develop and market ZEGFROVY (sunvozertinib), an oral, irreversible epidermal…
Treating acute ischemic strokes involves a precarious clinical balance: physicians must dissolve arterial clots to save brain tissue without triggering catastrophic intracranial hemorrhaging. To address the severe bleeding risks associated…
Editor's Note: Patient Worthy is honored to share the following article, originally published by our friends at CURE SYNGAP1. To see the article in its original format, please click here.…
A Sustainable Biologic Solution Gains Major Insurance Coverage and Proves Superior to Synthetic Alternatives in Real-World Clinical Data In the world of advanced wound care and reconstructive surgery, an unlikely…
As reported on PharmaBiz, a new study published in Cell Stem Cell highlights a promising approach to cancer immunotherapy that combines stem cell technology with personalized tumor targeting. Researchers from…
As reported on BioPharmaDive, Moderna captured attention this week with two major developments: a multibillion-dollar financing initiative aimed at expanding its oncology portfolio and regulatory clearance for its latest COVID-19…
As reported on PR NewsWire, Orsini has been named a specialty pharmacy partner for Priovant’s LISRAYA™ (brepocitinib), a once-daily oral treatment recently approved by the US Food and Drug Administration…
As reported on Healio, the phase 3 CARDIO-TTRansform study, the largest clinical trial conducted to date in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), found that adding eplontersen to contemporary…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
